Other languages Medicenna Therapeutics Corp.

Equities

MDNA

CA58490H1073

Market Closed - Toronto S.E. Other stock markets 01:28:54 30/04/2024 am IST			5-day change	1st Jan Change
2.31 ^CAD	-7.23%		+50.98%	+450.00%

26/04	Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding	CI
24/04	Medicenna Therapeutics Up 13% After Flagging Presentations	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medicenna Therapeutics Up 13% After Flagging Presentations	24/04
Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study	10/04
Medicenna Therapeutics Down 11% as it Presents Updated Preclinical Data on MDNA113 at AACR 2024	09/04
Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting	06/03
Medicenna Reports Q3 Net Loss $5.0 Million	14/02
Medicenna Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02
Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors	13/02
Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck?s Pembrolizumab	09/01
Medicenna Therapeutics Extends Period to Exercise Certain Warrants; Down 1.2%	23/12
Medicenna Announces "Compelling" Survival Benefit From Phase 2b Study in Recurrent Glioblastoma at NeuroOncology Meeting	17/11
Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp	17/11
Medicenna Reports Q2 Net Loss of $0.05 Per Share; Cash Runway Extended Into Q1 of Calendar 2025	14/11
Medicenna Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	14/11
Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma	09/11
Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting	09/11
Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer	06/11
Medicenna Presents Preclinical Data on MDNA113 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer	04/11
Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer	03/11
Medicenna Slumps 24% As Reports Nasdaq Delisting, Downsizes Management Team	27/23/27
Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Business Officer	27/23/27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Medicenna Therapeutics Corp.

Equities

MDNA

CA58490H1073

Other languages

Filters